Parallel Robotics

Why it fits

A surgical device company with one FDA-cleared product. It sits at the medical edge of a robotics mandate, not in industrial robotics, defense or energy. Open question: whether the NSF-funded manipulator becomes a lower-cost alternative to surgical robots.

Stage and round

Form D filed 21 September 2026 by Parallel Robotics, Inc. (Delaware): $7,310,193 sold of $11,310,187 to 32 investors, first sale 28 August 2026. Per the filing, the offering includes preferred stock issued on conversion of $6,310,206 of notes. No investors are named. In the LLC's name: a $250,000 state-program convertible debt investment (October 2024), FDA clearance (May 2026) and a $305,000 NSF SBIR Phase I award (July 2026).

Ask on the first call

1. 01Of the $7,310,193 sold, how much is new cash and how much is the $6,310,206 of converted notes, who led, and at what price?
2. 02How are Parallel Robotics, Inc. and Parallel Robotics LLC related, and do the FDA clearance, NSF award and University of Michigan license now sit with the corporation?
3. 03What is the commercial plan for the MediBot Needle Driver Uno: price, manufacturer, and has it been used in a clinical case or sold to a hospital?
4. 04Is Shorya Awtar full time at the company or an active professor, and what is headcount (SBIR.gov lists 13, the state report 1.0 FTE at September 2025)?

Risks

• –Sector fit and evidence. A regulated medical device for hospitals, not industrial robotics, defense, energy or manufacturing. The 510(k) summary says performance was evaluated primarily through non-clinical testing.
• –Round composition. The offering includes preferred stock from conversion of $6,310,206 of notes against $7,310,193 sold, $3,999,994 is unsold, and the filing names no lead or institutional investor.
• –Entity structure. Core patents are licensed from the University of Michigan to the LLC. No source read says how its license, clearance and grant relate to the Delaware corporation.

Could not confirm

• ?If the converted notes are counted in the amount sold, new cash so far is $999,987. The filing does not say so.
• ?Not confirmed whether the University of Michigan's Accelerate Blue Fund or any other named fund took part in the 2026 offering.
• ?A fundup.ai search snippet labels the offering a Series A. The Form D does not name the round.